Literature DB >> 23540800

Drug-induced parkinsonism.

José López-Sendón1, Maria A Mena, Justo G de Yébenes.   

Abstract

INTRODUCTION: Drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism after idiopathic Parkinson's disease (iPD). Initially reported as a complication of antipsychotics, it was later recognized as a common complication of antidepressants, calcium channel antagonists, gastrointestinal prokinetics, antiepileptic drugs and many other compounds. Despite being a major health problem in certain populations, it seems to be frequently overlooked by the medical community. AREAS COVERED: This paper approaches the concept of DIP, reviews its epidemiology, clinical features and ancillary tests recommended for a correct diagnosis. The authors discuss the different drugs and its pathogenic mechanisms. The relevance of an early recognition and recommendations for a correct management are commented. EXPERT OPINION: Prescribers need to remain vigilant for DIP, particularly in the elderly, patients taking multiple drugs and those with genetic risk factors involved in iPD. Cessation of the causing agent is the main treatment and there is no evidence of benefit for the use of anticholinergics or levodopa. If the medication cannot be withdrawn, it should be switched to agents with a lower risk of DIP.

Entities:  

Mesh:

Year:  2013        PMID: 23540800     DOI: 10.1517/14740338.2013.787065

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  29 in total

1.  Practice recommendations for Parkinson's disease: Assessment and management by community pharmacists.

Authors:  Tejal Patel; Feng Chang
Journal:  Can Pharm J (Ott)       Date:  2015-05

2.  Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype.

Authors:  Renato P Munhoz; Delcio Bertucci Filho; Hélio A G Teive
Journal:  Neurol Sci       Date:  2016-11-16       Impact factor: 3.307

3.  High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study.

Authors:  Shin-Chia Tsai; Shiow-Yunn Sheu; Li-Nien Chien; Hsin-Chien Lee; Eunice Jia-Shiow Yuan; Rey-Yue Yuan
Journal:  Br J Clin Pharmacol       Date:  2018-06-19       Impact factor: 4.335

4.  NADPH ameliorates MPTP-induced dopaminergic neurodegeneration through inhibiting p38MAPK activation.

Authors:  Jing-Si Zhou; Zhou Zhu; Feng Wu; Ying Zhou; Rui Sheng; Jun-Chao Wu; Zheng-Hong Qin
Journal:  Acta Pharmacol Sin       Date:  2018-05-16       Impact factor: 6.150

5.  Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-08

6.  Cardiovascular Autonomic Dysfunction in Patients with Drug-Induced Parkinsonism.

Authors:  Joong Seok Kim; Dong Woo Ryu; Ju Hee Oh; Yang Hyun Lee; Sung Jin Park; Kipyung Jeon; Jong Yun Lee; Seong Hee Ho; Jungmin So; Jin Hee Im; Kwang Soo Lee
Journal:  J Clin Neurol       Date:  2016-10-07       Impact factor: 3.077

7.  Substantia Nigra Echogenicity Predicts Response to Drug Withdrawal in Suspected Drug-Induced Parkinsonism.

Authors:  Jose L López-Sendón Moreno; Araceli Alonso-Cánovas; Javier Buisán Catevilla; Nuria García Barragán; Iñigo Corral Corral; Alicia de Felipe Mimbrera; María Consuelo Matute Lozano; Jaime Masjuan Vallejo; Juan Carlos Martínez-Castrillo
Journal:  Mov Disord Clin Pract       Date:  2015-12-18

8.  Cognitive Dysfunction in Drug-induced Parkinsonism Caused by Prokinetics and Antiemetics.

Authors:  Hyun Jung Ahn; Woo-Kyoung Yoo; Jaeseol Park; Hyeo-Il Ma; Yun Joong Kim
Journal:  J Korean Med Sci       Date:  2015-08-13       Impact factor: 2.153

9.  Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study.

Authors:  Manuel Menéndez-González; Francisco Tavares; Nahla Zeidan; José M Salas-Pacheco; Oscar Arias-Carrión
Journal:  Front Aging Neurosci       Date:  2014-04-01       Impact factor: 5.750

10.  Neuroleptic-induced Parkinsonism: Clinicopathological study.

Authors:  Umar A Shuaib; Ali H Rajput; Christopher A Robinson; Alex Rajput
Journal:  Mov Disord       Date:  2015-12-11       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.